Evidence map›Paper›PMID 34956863›Full record

ArticleFrontiers in oncology2021

Predictive and Prognostic Effects of Primary Tumor Size on Colorectal Cancer Survival.

Olatunji B Alese, Wei Zhou, Renjian Jiang, Katerina Zakka, Zhonglu Huang, Chimuanya Okoli, Walid L Shaib, Mehmet Akce, Maria Diab, Christina Wu and 1 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Mechanisms of metastatic colorectal cancer.Nature reviews. Gastroenterology & hepatology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Olatunji B AleseDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Wei ZhouWinship Data and Technology Applications Shared Resource, Emory University, Atlanta, GA, United States.
Renjian JiangWinship Data and Technology Applications Shared Resource, Emory University, Atlanta, GA, United States.
Katerina ZakkaDepartment of Medicine, Wellstar Atlanta Medical Center, Atlanta, GA, United States.
Zhonglu HuangWinship Data and Technology Applications Shared Resource, Emory University, Atlanta, GA, United States.
Chimuanya OkoliDepartment of Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, United States.
Walid L ShaibDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Mehmet AkceDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Maria DiabDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Christina WuDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.
Bassel F El-RayesDepartment of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPathologic staging is crucial in colorectal cancer (CRC). Unlike the majority of solid tumors, the current staging model does not use tumor size as a criterion. We evaluated the predictive and prognostic impact of primary tumor size on all stages of CRC.

methodsUsing the National Cancer Database (NCDB), we conducted an analysis of CRC patients diagnosed between 2010 and 2015 who underwent resection of their primary cancer. Univariate and multivariate analyses were used to identify predictive and prognostic factors, Kaplan-Meier analysis and Cox proportional hazards models for association between tumor size and survival.

resultsAbout 61,000 patients met the inclusion criteria. Median age was 63 years and majority of the tumors were colon primary (82.7%). AJCC stage distribution was: I - 20.1%; II - 32.1%; III - 34.7% and IV - 13.1%. The prognostic impact of tumor size was strongly associated with survival in stage III disease. Compared to patients with tumors <2cm; those with 2-5cm (HR 1.33; 1.19-1.49; p<0.001), 5-10cm (HR 1.51 (1.34-1.70; p<0.001) and >10cm (HR 1.95 (1.65-2.31; p<0.001) had worse survival independent of other variables. Stage II treated without adjuvant chemotherapy had comparable survival outcomes (HR 1.09; 0.97-1.523; p=0.148) with stage III patients who did, while Stage II patients who received adjuvant chemotherapy did much better than both groups (HR 0.76; 0.67-0.86; p<0.001). Stage III patients who did not receive adjuvant chemotherapy had the worst outcomes among the non-metastatic disease subgroups (HR 2.66; 2.48-2.86; p<0.001). Larger tumors were associated with advanced stage, MSI high, non-rectal primary and positive resection margins.

conclusionsFurther studies are needed to clarify the role of tumor size in prognostic staging models, and how to incorporate it into therapy decisions.

Indexed as

colorectal cancerprimary tumor sizeprognostic factorssurvival outcomestherapy response determinants

Identifiers

PMID34956863
PMCPMC8695445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.